Apexigen (APGN) to Be Acquired by Pyxis Oncology (PYXS) at $0.64 Per Share
by Marlena Haddad on 2023-05-25 at 11:53am

Apexigen (NASDAQ: APGN), which recently combined with Brookline Capital in July 2022, announced that it will be acquired by Pyxis Oncology (NASDAQ:PYXS) in an all-stock transaction that would value it at $0.64 per share.

For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock for a total enterprise value of approximately $16 million.

Under the terms of the agreement, Pyxis Oncology expects to issue approximately 4.4 million shares of its common stock to Apexigen stockholders to acquire the company. Current stockholders of Pyxis Oncology will own approximately 90% of the combined company and Apexigen’s stockholders are expected to own 10%.

Pyxis Oncology last closed at $3.34 and so the price represents a 10.4% premium over Apexigen’s last closing price of $0.58.

Apexigen and Brookline Capital originally intended to raise $73 million through the merger, but were only able to generate $19 million in gross proceeds. After just six months of being a public company, Apexigen announced that it was evaluating strategic alternatives and implementing a corporate restructuring to extend its cash runway, which resulted in laying off 55% of its team.

With a shared vision of bringing innovative solutions to oncology patients, Pyxis expects to complete the all-stock transaction with Apexigen by mid-2023. Upon closing of the transaction, the combined company will trade on Nasdaq under the ticker symbol “PYXS” and the existing Pyxis Oncology leadership team will continue to be responsible for all executive positions.

Pyxis Oncology, Inc. is a clinical-stage company focused on defeating difficult-to-treat cancers and is building next-generation therapeutics that hold the potential for mono and combination therapies.

 

 

Recent Posts
by Nicholas Alan Clayton on 2023-09-29 at 8:34am

Mobiv Acquisition Corp. (NASDAQ:MOBV) announced this morning that its shareholders approved its combination with EV motorcycle-maker SRIVARU at a special meeting September 28. Redemptions whittled Mobiv’s IPO share pool of 10,005,000 down to 195,992 through the vote. But, on September 27, Mobiv provided an update exhorting redeemers to change their decisions, noting that its ex-redemptions...

by Nicholas Alan Clayton on 2023-09-29 at 7:03am

Hennessy Capital Investment Corp VI (NASDAQ:HCVI) announced overnight that it plans to adjourn today’s 9 am ET extension vote and reopen it at 3 pm ET this afternoon. This does not technically change the redemption deadline for investors, but those wishing to withdraw their redemption requests may still do so by 2 pm ET today....

by Kristi Marvin on 2023-09-28 at 5:32pm

Latest SPAC Liquidations: Schultze Special Purpose Acquisition Corp. II Schultze Special Purpose Acquisition Corp. II (SAMA) to Liquidate on October 11, 2023 Schultze Special Purpose Acquisition Corp. II (Nasdaq: SAMA), announced that it will redeem all of the outstanding shares of its Class A common stock effective as of October 11, 2023. The Company expects...

by Kristi Marvin on 2023-09-28 at 4:40pm

Mercato Partners Acquisition Corporation (NASDAQ:MPRA) announced this afternoon via 8-K that its shareholders have approved its combination with Nuvini at a special meeting held earlier today. With 79.74% of the voting power of the Common Stock participating in the vote, the combination was overwhelmingly approved.  7,975,698 shares were recorded voting for the transaction, while only 38,008...

by Nicholas Alan Clayton on 2023-09-28 at 11:45am

Home Plate Acquisition Corporation (NASDAQ:HPLT) announced that it adjourned this morning’s extension vote without conducting any business and it will pick things up again at 11 am ET October 2. Shareholders at the meeting are to consider giving Home Plate an extra two and half months to complete a deal, moving its deadline from October...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved